Fig. 2
From: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
Disease progression timeline highlighting the diverse treatment and concurrent molecular events. a Both circulating and sputum IL5+ ILC2s is plotted as a percentage of a total number of enumerated ILC2s (protocol described in [5]), along with sputum IL-5 levels (see Additional file 1: online repository for methods) on the right Y axis. b Representative images of the ANA reactivities of sputum samples collected at the given dates is presented here (see Additional file 1: online repository for method and validation)